PBYI NASDAQ
Credit Risk of going bust: lower than 76% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.9%), Puma Biotechnology, Inc. would be worth roughly what it owes.
Total debt $4.8M against a stock market value of $560.1M.
Distance to default 8.78 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.4M (short-term plus half of long-term), stock volatility 60.8%; Altman Z'' -14.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Los Angeles, CA 90024
US
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| WILSON TROY EDWARD | S-Sale | 5,000 | $9.10 | 2026-09-14 |
| Cesano Alessandra | M-Exempt | 50,000 | $2.93 | 2026-09-14 |
| Cesano Alessandra | S-Sale | 62,150 | $9.12 | 2026-09-14 |
| Cesano Alessandra | M-Exempt | 50,000 | $2.93 | 2026-09-14 |
| AUERBACH ALAN H | S-Sale | 44,058 | $8.26 | 2026-07-06 |